ArticleScientific reports2025
Trends of ciprofloxacin use in Kazakhstan, impacts of COVID-19, and strategies for AMR control.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A National Forecast and Clinical Analysis of Pediatric Acute Mastoiditis in Kazakhstan.Children (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The misuse of antibacterial agents is a key driver of the rapid and widespread rise in antimicrobial resistance (AMR). This study examines the consumption trends of ciprofloxacin-the second most consumed antibiotic in Kazakhstan across outpatient and inpatient settings-before, during, and after the COVID-19 pandemic to inform AMR mitigation strategies. The analysis is based on two data sources: a comprehensive review of national regulatory documents governing ciprofloxacin use and a pharmaco-epidemiological assessment of procurement data provided by Vi-ORTIS. Ciprofloxacin consumption (ATC group J01MA02) from 2017 to 2023 was quantified in DDD/1000 inhabitants/day (DID) via the ATC/DDD methodology. Only 16 of 50 recommendations in national protocols align with the ciprofloxacin prescribing guidelines established in international standards. During the pandemic, ciprofloxacin use increased, with total and outpatient consumption peaking in the third quarter of 2020, whereas inpatient consumption peaked earlier in the second quarter. In the post pandemic period, inpatient consumption steadily declined, reaching 0.06 DID in 2023. The persistent increase in the use of "Watch" antibiotics, including ciprofloxacin, has raised concerns for Kazakhstan's healthcare system. Strengthening antimicrobial stewardship programs, implementing targeted interventions, and enhancing surveillance efforts are essential to curbing antibiotic overuse and safeguarding public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.